Category

Pharma

refill of liquid on tubes
CompanyDeep DiveAug 5, 2026

​Eli Lilly Stock Climbs as GLP-1 Demand Fuels Higher Sales Outlook

Eli Lilly (LLY) shares surged on Wednesday after the pharmaceutical giant raised its full-year sales forecast and delivered second-quarter results that beat expectations.

GLPLLY
Hims & Hers Dives on FDA Crackdown, Sending Shockwaves Through Weight-Loss Drug Trade cover
CompanyDeep DiveFeb 9, 2026

Hims & Hers Dives on FDA Crackdown, Sending Shockwaves Through Weight-Loss Drug Trade

Hims & Hers (HIMS) took a steep dive after U.S. regulators signaled an aggressive move against compounded versions of blockbuster weight-loss medicines, shaking investor confidence in one of the fastest-growing corners of digital health.

HIMSGLPIP
orange and white medication pill
CompanyDeep DiveJan 8, 2026

Amneal Pharmaceuticals’ 2026 Outlook: Can the Rally Extend After a 70% Run?

Amneal Pharmaceuticals (AMRX) has entered 2026 with powerful momentum after a year that reshaped investor sentiment around the stock.

AMRX
Day One Just Made A Bold Bet On Mersana — Here’s What It Could Mean cover
CompanyDeep DiveNov 17, 2025

Day One Just Made A Bold Bet On Mersana — Here’s What It Could Mean

Day One Biopharmaceuticals is acquiring Mersana Therapeutics in a deal worth up to $285M, adding a novel B7-H4–targeting ADC and strengthening its rare-cancer pipeline alongside OJEMDA’s momentum.

DAWN
Avadel’s $2.1 Billion Deal With Alkermes Could Shake Up Sleep Medicine—Here’s How! cover
CompanyDeep DiveOct 30, 2025

Avadel’s $2.1 Billion Deal With Alkermes Could Shake Up Sleep Medicine—Here’s How!

Avadel Pharmaceuticals’ $2.1B acquisition by Alkermes underscores Lumryz’s strong growth and profitability, with added upside tied to FDA approval for a new sleep disorder indication.

AVDLALKSJAZZ
The Novavax Crisis Deepens: Why Shah Capital Wants Out Now! cover
CompanyDeep DiveOct 24, 2025

The Novavax Crisis Deepens: Why Shah Capital Wants Out Now!

Novavax faces pressure from a major shareholder Shah Capital to explore a sale as it struggles with weak revenue, poor execution, and fading relevance post-COVID-19.

NVAX
Harrow’s MELT Acquisition Could Disrupt IV Sedation—But Is It The Hottest Pharma Small-Cap Buy? cover
CompanyDeep DiveOct 2, 2025

Harrow’s MELT Acquisition Could Disrupt IV Sedation—But Is It The Hottest Pharma Small-Cap Buy?

Harrow Inc. targets Melt Pharma buyout to expand sedation portfolio with MELT-300, a sublingual non-IV sedative, aiming for U.S. launch and global partnerships while diversifying beyond ophthalmics.

HROW
Y-mAbs’ $412 Million Take-Private Offer From SERB Poised To Upset The Oncology Landscape cover
CompanyDeep DiveAug 13, 2025

Y-mAbs’ $412 Million Take-Private Offer From SERB Poised To Upset The Oncology Landscape

Y-mAbs Therapeutics stunned investors when SERB Pharmaceuticals announced an all-cash bid to take the company private at $8.60 per share, valuing the deal at approximately $412 million.

YMAB
Abbvie’s $1 Billion Gilgamesh Gambit: The Deal That Could Rewrite Its Future! cover
CompanyDeep DiveAug 7, 2025

Abbvie’s $1 Billion Gilgamesh Gambit: The Deal That Could Rewrite Its Future!

AbbVie’s recent confirmation that it’s in talks to acquire Gilgamesh Pharmaceuticals for roughly $1 billion underscores its unrelenting push to replenish growth after Humira’s patent cliff.

ABBV
Merck’s $10 Billion Bet On Verona: Smart Strategic Pivot Or Costly Diversion From The Keytruda Cliff? cover
CompanyDeep DiveJul 22, 2025

Merck’s $10 Billion Bet On Verona: Smart Strategic Pivot Or Costly Diversion From The Keytruda Cliff?

Merck has made headlines yet again with its $10 billion acquisition of Verona Pharma, a bold move aimed at cushioning the impending blow from the loss of exclusivity on its cancer drug Keytruda.

MRK
Eli Lilly’s Obesity Pill Could Be a Game-Changer — But Here's Why Zepbound Already Has a Giant Lead cover
BiotechMarket MoversJul 17, 2025

Eli Lilly’s Obesity Pill Could Be a Game-Changer — But Here's Why Zepbound Already Has a Giant Lead

Eli Lilly has taken a commanding position in the obesity drug market with its GLP-1 agonist Zepbound, and now the pharma giant is preparing for its next leap: a daily oral pill named orforglipron.

LLY
Hims & Hers Stock Plunges After Novo Nordisk Breakup: What Really Happened? cover
CompanyDeep DiveJul 3, 2025

Hims & Hers Stock Plunges After Novo Nordisk Breakup: What Really Happened?

Hims & Hers Health saw its stock crash by over 35% in a matter of days after Novo Nordisk announced the termination of its short-lived partnership over the weight loss drug Wegovy.

HIMSNVO
Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease! cover
CompanyDeep DiveJun 25, 2025

Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease!

Eli Lilly has expanded into cardiovascular treatment with its $1.3 billion acquisition of Verve Therapeutics, a clinical-stage gene-editing company focused on one-time therapies to lower cholesterol and prevent heart disease.

LLY
ASBP: Unlocking Multi-Billion Dollar Markets with Enhanced Drug Delivery cover
CompanyDeep DiveMar 25, 2025

ASBP: Unlocking Multi-Billion Dollar Markets with Enhanced Drug Delivery

Enter Aspire Biopharma, Inc. (NASDAQ: ASBP), a pioneering company enhancing existing drugs with their patent-pending, soluble sublingual technology. By delivering therapeutic levels of medication rapidly and directly into the bloodstream, Aspire is poised to revolutionize how drugs and supplements are delivered and absorbed.

ASBP
Decoded: Why Did Johnson & Johnson Spend $2 billion To Acquire Ambrx Biopharma? cover
Market MoversPharmaJan 20, 2024

Decoded: Why Did Johnson & Johnson Spend $2 billion To Acquire Ambrx Biopharma?

In a groundbreaking move, pharmaceutical giant Johnson & Johnson has set the stage for a significant leap forward in cancer treatment with its recent $2 billion acquisition of Ambrx Biopharma.

AMAMJNJ
TG Therapeutics: Is It Time to Invest In This Biotech Player After The Unprecedented 36.4% Jump? cover
BreakingMarket MoversNov 9, 2023

TG Therapeutics: Is It Time to Invest In This Biotech Player After The Unprecedented 36.4% Jump?

TG Therapeutics' stock soared an astonishing 36.4% higher in a single session on the heels of the company's impressive third-quarter results.

TGTX
OKYO Pharma: An Emerging Biopharma Smallcap With Game Changing Treatments In Ophthalmology cover
BiotechPharmaMar 2, 2023

OKYO Pharma: An Emerging Biopharma With Game Changing Treatments In Ophthalmology

OKYO Pharma's main drug has already surpassed Phase 1 and reached Phase 2. OK-101 is catering to niches within the domain of ophthalmic diseases and is expected to see its core drug candidate in Phase 2 of clinical trials in the very near future.

OKYO
NanoKnife FDA Approval Is The Highlight Of An Otherwise Tepid AngioDynamics Quarter
BiotechHealthcareApr 3, 2019

NanoKnife FDA Approval Is The Highlight Of An Otherwise Tepid AngioDynamics Quarter

Latham, New York: AngioDynamics, Inc. (NASDAQ:ANGO) is a number one supplier of modern, minimally invasive medical units utilized by skilled healthcare suppliers for vascular entry, peripheral vascular illness, and oncology. It just lately reported its monetary outcomes for the third quarter of the fiscal 12 months 2019 ending 28th February 19 whereby the co

ANGO
Lexicon’s Volatility Could Be Your Friend After The Zynquista Rejection
BiotechHealthcareApr 2, 2019

Lexicon’s Volatility Could Be Your Friend After The Zynquista Rejection

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is an organization identified for locating novel drug targets and drug candidates developed from state-of-the-art medicinal chemistry and proprietary gene. The firm lately produced a superb outcome beating Wall Street expectations with the administration anticipating a 20% income development in 2019, pushed by Euro

LXRXSNY
Amphastar Had A Good 2018 With Multiple ANDA Approvals
HealthcareNewsMar 18, 2019

Amphastar Had A Good 2018 With Multiple ANDA Approvals

Rancho Cucamonga, CA: Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) is a specialty pharmaceutical firm that focuses totally on creating, manufacturing, advertising, and promoting technically-challenging generic and proprietary injectable, inhalation, intranasal merchandise, and insulin API merchandise. It launched its outcomes for the fourth quarter and full

AMPH
Aerie Pharmaceuticals Delivers Mixed Result; Focus On International Expansion
BiotechHealthcareFeb 27, 2019

Aerie Pharmaceuticals Delivers Mixed Result; Focus On International Expansion

Durhan, NC: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a scientific stage pharmaceutical firm targeted on offering therapies for the therapy of eye-related illnesses, launched its quarterly outcomes for the interval ended December 31,2018. The firm delivered its third consecutive blended outcome with a income beat however with an earnings miss. The administr

AERI
Mallinckrodt spinoff to include 7 manufacturing sites in U.S. and Japan
PharmaDec 29, 2018

Mallinckrodt spinoff to include 7 manufacturing sites in U.S. and Japan

[ad_1] With its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with a large controlled substances and acetaminophen business and seven manufacturing facilities split between the U.S. and Japan. The Dublin-based drugmaker this month announced its intent to spin off its Specialty Generics business, which will keep

APIDEA
Amgen pays $50M for Molecular Partners’ preclinical Anti-cancer
BiotechNewsDec 19, 2018

Amgen pays $50M for Molecular Partners’ preclinical Anti-cancer

Amgen is paying Molecular Partners $50 million (€44 million) upfront for world rights to preclinical anti-cancer immune cell activator MP0310. The companions will take a look at the 4-1BB-FAP bispecific molecule together with Amgen medicine together with its bispecific T-cell engagers. Antibodies focusing on T cell co-stimulatory receptor 4-1BB, also referre

FAP
Orchard Therapeutics commits to gene therapies production facility with plans to hire 100 workers
PharmaDec 13, 2018

Orchard Therapeutics commits to gene therapies production facility with plans to hire 100 workers

[ad_1] Orchard Therapeutics mentioned it supposed to use a few of the proceeds of an IPO to construct a producing facility for its gene therapies program and now it's. With about $225 million in hand from the IPO, the biotech will spend a lot of that on a plant in California. The transatlantic biotech announced on Thursday ...

EUADASCID
GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'
PharmaDec 10, 2018

GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'

[ad_1] In the face of "unprecedented" demand for its shingles vaccine, GlaxoSmithKline is doing every little thing it may to enhance provide. But regardless of these efforts—it shipped as a lot vaccine within the third quarter because it did within the first half of the yr—GSK says the Shingrix shortage will persist into 2019. Over ...

GSKTV
Generics 'cartel' probe expands to a whopping 300 drugs: report
PharmaDec 10, 2018

Generics 'cartel' probe expands to a whopping 300 drugs: report

[ad_1] A probe into generic drug value fixing has grown to embrace 300 medication, in accordance to The Washington Post. (Pixabay) Years into a authorities probe over alleged generic drug value fixing, investigators have expanded the scope to embrace 300 medication and 16 corporations, an official told The Washington Post. Connecticut Assistant Attorney Gene

Akorn's CEO bows out after failing last-ditch bid to save Fresenius merger
PharmaDec 10, 2018

Akorn's CEO bows out after failing last-ditch bid to save Fresenius merger

[ad_1]  Akorn as soon as once more tried and failed to salvage its $4.3 billion merger with Fresenius. Delaware's high court docket dominated that Fresenius had nixed the deal legally after knowledge issues cropped up, and within the wake of the choice, Akorn's CEO made his exit. Only days after attorneys for Akorn and Fresenius ...

Citius Pharmaceuticals (NASDAQ: CTXR) Successfully Raises $10 Million
NewsPharmaNov 23, 2018

Citius Pharmaceuticals (NASDAQ: CTXR) Successfully Raises $10 Million

Citius Pharmaceuticals Successfully Raises $10 Million – CTXR announced today that the Company completed the largest capital raise in its history of $10 million, and insiders were responsible for supporting 50% of the raise. Mr. Myron Holubiak, President and CEO of Citius Pharmaceuticals, invested $1 Million in the Company and Mr. Leonard Mazur, Executive Ch

CTXR
Disclosure, finances, and the oncologist
PharmaSep 11, 2018

Disclosure, finances, and the oncologist

[ad_1] Conflict-of-interest guidelines missing enforcement According to the BMJ, oncologists in the US have an issue with disclosure. Research in the journal JAMA Oncology has revealed a major variety of US oncologists are failing to reveal funds from trial sponsors. Researchers now know that quite a few FDA-approved medicines that efficiently handed trials

BMJUSJAMA
Cutting-edge biotech spurring growth in infectious disease testing
PharmaSep 5, 2018

Cutting-edge biotech spurring growth in infectious disease testing

[ad_1] Increase in adoption of superior applied sciences equivalent to molecular & fast techniques, rise in incidence of infectious illnesses, and rising consciousness of infectious illnesses are anticipated to spice up the infectious disease testing market by means of 2023. According to a brand new examine by Allied Market Research, the worldwide IVD market

IVDCAGRAG
Trial to test if light can reduce side effects of cancer treatment
PharmaAug 28, 2018

Trial to test if light can reduce side effects of cancer treatment

[ad_1] A pioneering UK trial led by Newcastle upon Tyne Hospitals Trust is about to take a look at whether or not a brand new method can reduce the ache of head and neck cancer treatment. The Lite Therapy Effectiveness For Oral Mucositis (LiTEFORM) trial will uncover if low degree laser treatment can assist in ...

UKNHSNIHR
Automation, IoT and the future of smarter research environments
PharmaAug 24, 2018

Automation, IoT and the future of smarter research environments

[ad_1] Technology and automation can be utilized to drive high quality and effectivity in manufacturing processes, enhancing drug growth by way of knowledge evaluation, course of monitoring, and steady suggestions. Big data, paperless processes, automation and cloud technologies are driving the laboratory informatics trade ahead, creating smarter research en

IQIPAITIOT
Microcatheter market to be worth $304.5m by 2026, says study
PharmaAug 14, 2018

Microcatheter market to be worth $304.5m by 2026, says study

[ad_1] The international microcatheter market was valued at $162.3 million in 2017 and is predicted to to attain almost $304.5m by 2026, increasing at a CAGR of round 7.5 per cent, in accordance to a brand new report, Rise in adoption of minimally invasive procedures, technological developments, improve in goal affected person inhabitants are doubtless ...

CAGRTMRUSCTO
Temperature Controlled Logistics Live 2018 – 13th March 2018
PharmaMay 31, 2018

Temperature Controlled Logistics Live 2018 – 13th March 2018

[ad_1] An on-line collection that includes reside interactive webinars, on-demand webinars, whitepapers, infographics, commentary articles and interviews all specializing in provide chain excellence with temperature sensiti… [ad_2] Source link

SCD
PharmaMay 25, 2018

Malaria: Scientists urged to not underestimate CRISPR’s dangers

[ad_1] Similar to new Hollywood feature Rampage, a current examine has urged the life sciences business not to underestimate the dangers that would cover inside CRISPR Cas9. Although the movie has been criticised for wildly exaggerating the capabilities of the gene enhancing method, it may be recognised for its effort to draw focus from the ...

WHORNADNA
SCD
PharmaMay 25, 2018

MHRA grants UK patients early access to treatment for painful genetic disorder

[ad_1] A treatment for a uncommon and debilitating genetic lipid disorder has been awarded a spot on the Early Access to Medicines Scheme by the MHRA.   The resolution signifies that eligible patients with familial chylomicronaemia syndrome (FCS )shall be ready to access volanesorsen, earlier than the European Commission (EC) makes a proper resolution for ..

MHRAUKFCSEC
SCD
PharmaMay 25, 2018

Physicians urged to talk money to end financial nightmares for cancer patients

[ad_1] As groundbreaking oncology therapies hand patients new hopes of survival, a whitepaper has urged the trade to deal with and stop the financial burdens that plague cancer patients. Cancer Related Financial toxicity or CRFT appears to be like on the crippling financial impacts that strike nearly all of adults struggling with a type of ...

CRFTUS
SCD
PharmaMay 25, 2018

Doctors and the influence of the digital boom

[ad_1] Doctors is likely to be extremely succesful, extremely competent people for whom saving a life is simply one other hour on the job. But they’re additionally individuals, searching for engagement and enjoyment of their day-to-day lives. And pharmaceutical firms are taking discover. Instant entry to the newest chatter isn’t simply reserved for millennia